ArticleBMC cancer2014
Tongue carcinoma infrequently harbor common actionable genetic alterations.
Article in BMC cancer, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 2 syntheses or guidelines pooled it, 37 citations in OpenAlex.
- Pooled it
- Prevalence of EGFR Tyrosine Kinase Domain Mutations in Head and Neck Squamous Cell Carcinoma: Cohort Study and Systematic Review.In vivo (Athens, Greece) · 2017Pooled it
- Smoking Status and Recurrence in Oral Tongue Squamous Cell Carcinoma: Evidence for Convergent Clinical Behavior.Laryngoscope investigative otolaryngology · 2026Article
- Omics-Derived Prognostic Biomarkers in Tongue Squamous Cell Carcinoma: A Systematic Review with Risk-of-Bias Appraisal and Translational Prioritization.Current issues in molecular biology · 2026Review
- DNA methylation analysis of the epigenome in oral squamous cell carcinoma.Human genomics · 2026Article
- Dual Disruption of EGFR/PI3K Signaling: IGF2BP2 Targeting Reverses Anti-EGFR Resistance in CAFs-Infiltrated Oral Squamous Cell Carcinoma.International journal of molecular sciences · 2025Article
- Single cell analysis in head and neck cancer reveals potential immune evasion mechanisms during early metastasis.Nature communications · 2023Article
- Mutational spectrum of tobacco associated oral squamous carcinoma and its therapeutic significance.World journal of surgical oncology · 2019Article
- Impact and Relevance of the Unfolded Protein Response in HNSCC.International journal of molecular sciences · 2019Review
- Beyond EGFR Targeting in SCCHN: Angiogenesis, PI3K, and Other Molecular Targets.Frontiers in oncology · 2019Review
- High expression of TMEM40 contributes to progressive features of tongue squamous cell carcinoma.Oncology reports · 2019Article
- Long non-coding RNA NEAT1 promotes migration and invasion of oral squamous cell carcinoma cells by sponging microRNA-365.Experimental and therapeutic medicine · 2018Article
- A review of the most promising biomarkers for early diagnosis and prognosis prediction of tongue squamous cell carcinoma.British journal of cancer · 2018Review
- Suppression of c-MET overcomes erlotinib resistance in tongue cancer cells.OncoTargets and therapy · 2018Article
- Therapeutic Implications of the Genetic Landscape of Head and Neck Cancer.Seminars in radiation oncology · 2018Review
- Nrf2 regulates cellular behaviors and Notch signaling in oral squamous cell carcinoma cells.Biochemical and biophysical research communications · 2017Article
- Long noncoding RNA EGFR-AS1 mediates epidermal growth factor receptor addiction and modulates treatment response in squamous cell carcinoma.Nature medicine · 2017Article
- Genomic sequencing and precision medicine in head and neck cancers.European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology · 2017Review
- Targeting non-canonical autophagy overcomes erlotinib resistance in tongue cancer.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2016Article
- Genetic determinants in head and neck squamous cell carcinoma and their influence on global personalized medicine.Genes & cancer · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundOral tongue squamous cell carcinomas (TSCC) are a unique subset of head and neck cancers with a distinct demographic profile, where up to half of the cases are never smokers. A small proportion of patients with OSCC are known to respond to EGFR TKI. We used a high-sensitivity mass spectrometry-based mutation profiling platform to determine the EGFR mutation status, as well as other actionable alterations in a series of Asian TSCC.
methods66 TSCC patients treated between 1998-2009 with complete clinico-pathologic data were included in this study. Somatic mutation profiling was performed using Sequenom LungCarta v1.0, and correlated with clinical parameters.
resultsMutations were identified in 20/66(30.3%) of samples and involved TP53, STK11, MET, PIK3CA, BRAF and NRF2. No activating EGFR mutations or KRAS mutations were discovered in our series, where just over a third were never smokers. The most common mutations were in p53 (10.6%; n = 7) and MET (10.6%, n = 11) followed by STK11 (9.1%, n = 6) and PIK3CA (4.5%, n = 3). BRAF and NRF2 mutations, which are novel in TSCC, were demonstrated in one sample each. There was no significant correlation between overall mutation status and smoking history (p = 0.967) or age (p = 0.360). Positive MET alteration was associated with poorer loco-regional recurrence free survival (LRFS) of 11 months [vs 90 months in MET-negative group (p = 0.008)]. None of the other mutations were significantly correlated with LRFS or overall survival. Four of these tumors were propagated as immortalized cell lines and demonstrated the same mutations as the original tumor.
conclusionsUsing the Sequenom multiplexed LungCarta panel, we identified mutations in 6 genes, TP53, STK11, MET, PIK3CA, BRAF and NRF2, with the notable absence of EGFR and HER2 mutations in our series of Asian OSCC. Primary cell line models recapitulated the mutation profiles of the original primary tumours and provide an invaluable resource for experimental cancer therapeutics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.